Abstract
In Canada the introduction of the Haemophilus influenzae type b (Hib) capsular polysaccharide-protein conjugate vaccines in 1988 led to a reduction in the annual incidence of Hib meningitis in children less than 5 years of age from approximately 44/100,000 in 1985 to &1/100,000 by 1994 (1). This reduction in morbidity and mortality was particularly dramatic among the Canadian Inuit, who had suffered the highest reported incidence of Hib meningitis (530/100,000 children less than 5 years) among indigenous populations worldwide (2).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
